CONTEXT AND OBJECTIVE: The possible role of adhesion molecules in early breast carcinogenesis has been shown in the literature. We aimed to analyze early adhesion imbalances in non-nodular breast lesions and their association with precursor lesions, in order to ascertain whether these alterations exist and contribute towards early carcinogenesis. DESIGN AND SETTING: Retrospective cross-sectional study based on medical records at a private radiological clinic in São Paulo, Brazil.
INTRODUCTION
Precursor lesions of the breast are considered to be entities with high potential to progress toward neoplastic transformation, but they lack the ability to invade and metastasize and, in this sense, are premalignant. 1 This broad concept includes most of the diagnostic categories exhibiting atypia, such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS).
Although presence of atypia alone is a robust marker for association with cancer, 2-4 some other lesions not necessarily harboring atypia or hyperplasia, such as microglandular adenosis and papillary lesions, have also been associated with invasive carcinoma. [5] [6] [7] Recently, microarray analysis on the triple negative subtype of ductal invasive carcinomas has indicated that actually there is a subset of these cases that does not express claudins. These cases were described as "claudin-low" and were characterized by statistically significantly worse prognosis. 8 Approximately 23 proteins have already been described as members of the claudin family, and these are essential for the tight junctions (TJs) that form between epithelial cells and between endothelial cells. 9 They play crucial roles in controlling paracellular transport and in maintaining cell polarity. 10 These findings shed light on the importance of adhesion molecules and their possible role in early breast carcinogenesis. Loss of claudin 4
has already been reported in cases of lobular in situ carcinoma. 11 However, cell adhesion is not limited to the claudin system.
Several complex molecular schemes contribute to cell adhesion, such as cadherins, integrins and CD4, which have previously been studied in relation to breast cancer. Other than these important components of the cell adherence system, some novel mechanisms are directly or indirectly involved in cell adhesion, cell stability and prevention of cell migration.
Focal adhesion sites contain multiple structural proteins such as talin, paxillin and focal adhesion kinase (FAK). 12 Paxillin is an adaptor protein with an important role in cell spreading and motility, 13 and is located in the region of cell contact with the underlying extracellular matrix. In the physiological state, it functions as an adaptor protein that recruits several cytoskeleton and signaling proteins into a complex, thereby enabling transmission of coordinated downstream signals.
14 Tyrosine phosphorylation of paxillin has been observed following integrin-dependent cell adhesion to extracellular matrix proteins, thus implicating paxillin in integrin-mediated signaling and focal adhesion formation. 14, 15 Few reports have described paxillin distribution in breast tissue and ductal carcinomas.
In addition, while mediating cell adhesion, many cell adhesion molecules that have already been described act as tumor suppressors. Disrupted cell-cell or cell-extracellular matrix (ECM) adhesion significantly contributes towards uncontrolled cell proliferation and progressive distortion of normal tissue architecture. 16 In this regard, another molecular pathway involved in cell adhesion, motility and invasion, with a potential role in breast cancer, is the AP-1 FRA-1 family. 17, 18 A recent study has
shown that high frequency of FRA-1 in ductal carcinoma in situ may be associated with early events in breast carcinogenesis, since the frequency of FRA-1 expression in invasive cancer was lower than the frequency of these in situ lesions. 19 Interestingly, there are several reports in the literature regarding interactions between HER-2 expression (one of the most important receptor kinase growth factors in breast cancer) and adhesion molecules.
HER-2 overexpression has previously been reported to be associated with claudin 4 20 and paxillin expression 21 in breast carcinomas, which led us to further investigate whether, in our set of non-nodular breast lesions, this association would be confirmed.
OBJECTIVES
Our aim was therefore to analyze possible early adhesion imbalances by assessing these markers (claudin, paxillin, HER-2 and FRA-1) in non-nodular breast lesions and their possible association with precursor lesions, in order to ascertain whether these alterations might be present and contribute towards early carcinogenesis.
METHODS
The medical records of all consecutive women attended between 
Biopsy method
Stereotaxic vacuum-assisted core biopsy was performed for histopathological analysis, using an 11-gauge needle and a vac- to reach the target area. X-rays were produced before and after obtaining specimens. Needle insertion was aimed towards the microcalcifications and, in cases of multiple foci, the most suspicious group according to the radiological appearance was chosen. The radiologist sought to obtain 15 to 18 specimens for histopathology. After concluding the biopsy procedure, a titanium clip was inserted, thus marking the biopsied area. Before being discarded, the needle was washed and the material remaining in the tubes was collected and subjected to further centrifugation.
Morphological assessment
All the specimens were identified and properly labeled with the patient's data. The samples were radiographed to ascertain whether microcalcifications were present, and were packaged in vials with 10% buffered formalin. The specimens were then processed and embedded in paraffin blocks, and slides of thickness 5 microns were obtained and stained with hematoxylin-eosin.
Further sections were subjected to immunohistochemical assays.
On morphological examination, the following catego- 
Immunohistochemistry
Control tissues were included in each reaction. Whole 5-μm tissue sections from each block were subjected to each essay (for claudin, paxillin, HER-2 and FRA-1), cut and transferred to silanized slides, and left to dry overnight at 56 ºC. The next day, the slides were dewaxed in xylene, rehydrated in graded alcohol and washed with water. Antigen retrieval was performed using a pressure cooker and 10 mM citrate buffer (pH 6.0).
The samples were quenched with 6% hydrogen peroxide and incubated overnight at 4 ºC with different antibodies, to be examined using immunohistochemistry. The following day, the slides were rinsed with PBS and incubated with the secondary antibody, for 30 min at 37 ºC. The slides were rinsed again with phosphate buffered saline (PBS) and incubated with polymer (Novolink Max Polymer cat# RE7260-K, Novocastra Lab, Newcastle upon Tyne, UK) for 30 min at 37 ºC. The slides were developed with 100 mg% DAB as the chromogen, with 0.06% hydrogen peroxide, and counterstained with Harris hematoxylin. Positive and negative control slides were included. The negative control was a slide from which the primary antibody had been omitted. Table 1 presents the primary antibodies and dilution rates utilized.
All reactions were performed in the Pathology Department of A.
C. Camargo Hospital, São Paulo.
Claudin-4, paxillin and HER-2 membrane expression were assessed by identifying ductal cells from their chicken-wire pattern staining, and were classified using the standard HER-2 classification system of Herceptest, as 1 to 3+. FRA-1 showed nuclearexclusive and diffuse staining. Lesions were defined as positive if at least 10% of the true neoplastic tumor cells expressed the protein.
Radiological assessment
The initial mammograms brought by patients from other services, including the BI-RADS 4 classification, were reviewed. All the cases were analyzed by two observers (trained radiologists) and were objectively reclassified in accordance with the fourth edition of BI-RADS. In the event of discordant classification, the two observers worked together to reach a consensus.
Statistical analysis
Spearman's rank test was used to estimate the relationships between staining patterns of different antibodies. The correlation between antigen expression and other parameters was studied using Pearson's chi-square or Fisher's exact test. System, Cary, NC, USA).
RESULTS
During the study period, 127 patients were evaluated and ful- Since the association between claudin-4 expression and HER-2 overexpression had previously been reported in breast carcinomas, 20 we investigated whether this association would be confirmed in our set of non-nodular breast lesions. We found that HER-2 expression marginally correlated with claudin-4 (P = 0.0734; Among the other proteins evaluated, claudin 4 expression was associated with paxillin (P < 0.001; Table 4 (Table 4) .
It did not correlate with HER-2 expression (P = 0.013) or with FRA-1 (P = 0.2443, Table 5 ).
FRA-1 expression was always evident around ductal structures, thus strongly marking the basal membrane (Figure 3).
Ductal cells were usually negative, but in normal ductal structures, some scattered elements showed nuclear-exclusive staining. In one third of the cases with normal breast tissue, more than 10% of the preserved ductal cells expressed FRA-1.
However, the majority of non-proliferative lesions, including papillary lesions, adenosis, apocrine metaplasia and columnar alterations remained diffusely negative. The reactivity to FRA-1 tended to be more intense and diffusely distributed in atypical and malignant lesions (13 out of 21 cases), with positive associations with atypia and malignancy (P = 0.04, Table 4 ). FRA-1 expression was also strongly associated with HER-2 expression (P < 0.001; in situ. 23 It seems that these events were not sampled in our series, or that they occur later on in breast carcinogenesis.
FRA-1 expression in normal and non-neoplastic breast tissue showed nuclear immunoreactivity, as reported by Song et al. 24 We did not find any example of cytoplasmic reactivity for FRA-1, even at in our single case of invasive carcinoma. This may be explained by the fact that this particular case was a mucinous well-differentiated carcinoma. However, we found a shift between benign and malignant lesions, particularly when atypical cases were merged with in situ carcinomas. While one third of the benign cases were FRA-1 positive, over 61% of the malignant cases showed some nuclear reaction to FRA-1 (P = 0.0475), concordant with the findings of Song et al. tissue cells. 27 It is possible that the momentum shortly before the impressive shift from in situ to invasive carcinoma, with focal infiltration, constitutes the most demanding situation for nuclear FRA-1 production.
In normal mammary cells, paxillin had previously seldom been described in humans, and the few reports available are
rather similar to what we have reported here. 12 On the other hand, invasive ductal carcinomas showed expression of 27.7%
(short S) to 50%. 12 We were able to describe paxillin expression with a wider range of functional alterations, and half of the benign cases were positive. In contrast to another report, 12 we did not find any association between paxillin expression and progression to malignancy or BI-RADS classification. However, when assessed in cytological smears, paxillin failed to reach any concordance with invasion or prognostic variables. 28 It remains unclear whether paxillin may be associated with invasion, since it regulates focal adhesion kinase (FAK) function, 29 which is a marker of malignant transformation rather than invasion. 30 A substantial set of malignant and premalignant cases needs to be evaluated in order to provide further responses to this question, since paxillin expression was correlated with claudin and FRA-1 expression in our cases (P < 0.001 and 0.013, respectively).
It appears that adhesion signals and complex cellular protein complexes are somehow interrelated, and that subtle imbalance of one settlement may interfere with others. Alternatively, it is possible that cellular signaling aiming towards switching the adhesion status is launched in a coordinated manner, which may affect some, if not all, adhesion complexes in a cascade.
There are several reports in the literature regarding interactions between HER-2 expression and adhesion molecules.
Paxillin expression was found to correlate with HER-2 gene amplification in 314 cases of invasive carcinoma, which led to speculation about whether paxillin might be a marker that could influence the predictive value of HER-2 regarding the response to adjuvant treatment. 21 We could not identify such a correlation, since the majority of our cases comprised benign and negative HER-2 samples, concordant with the findings of Madan et al. 12 Claudin-4 was found to correlate with HER-2 immunohistochemical expression in 299 cases of invasive ductal carcinoma, 20 but another report did not find this correlation in 412 tumors. 31 In our series, this correlation was also not found (P = 0.0734). It seems that the larger contingent of nonneoplastic cases impeded a more specific correlation between these two variables.
Finally, we were able to report a statistically significant correlation between HER-2 and FRA-1 expression (P < 0.001).
Since both of these variables also statistically correlated with the radiological and morphological results in this set of non-nodular breast lesions, a larger series of premalignant and malignant cases is essential in order to clarify the possible significance of these findings.
CONCLUSION
We conclude that, although already present in smaller amounts, imbalance of adhesion molecules is not necessarily prevalent in non-nodular breast lesions. Moreover, since FRA-1 expression reached statistically significant correlations with radiological and morphological diagnoses and with HER-2 status, perhaps this expression should be evaluated in a larger series, in order to investigate its potential predictive role in this setting.
